Addiction Treatment Pioneer Dr. Wilson Joins Influential DC Health Council

GIG HARBOR, Wash. – May 08, 2026 – Dr. Amanda Wilson, a physician and entrepreneur known for her technology-forward approach to addiction medicine, has been named to The Washington Post Intelligence Health Care Council, an exclusive appointment that places a leading voice for virtual treatment at the heart of national policy discussions.

Dr. Wilson is the CEO and Co-Founder of NorthStar, a company pioneering a fully virtual, year-long addiction treatment program. Her appointment to the invitation-only council—a forum of senior executives and policymakers who convene to shape the future of American medicine—signals a significant moment for the digital health sector. It suggests that innovative, and sometimes disruptive, models of care are gaining serious consideration in the highest echelons of the healthcare industry.

Operating independently from The Washington Post's newsroom, the council is part of a premium suite of services designed to connect influential leaders. For Dr. Wilson, it provides a powerful platform to advocate for new solutions to a crisis that affects nearly 50 million Americans.

"Health care in America stands at an inflection point, and the decisions we make today will define the system our children inherit tomorrow," Dr. Wilson stated. "It is a profound honor to join this remarkable council of leaders who share an unwavering commitment to bold, evidence-based solutions. I look forward to bringing the voice of patients, clinicians, and innovators to these critical conversations."

The NorthStar Model: A Virtual Revolution in Recovery?

At the core of Dr. Wilson's influence is NorthStar's ambitious and data-driven treatment model. The company eschews traditional brick-and-mortar clinics for a fully virtual, year-long program that it claims treats addiction at its biological root. This approach is built on a foundation of cutting-edge science and intensive, personalized support.

Each patient is assigned a dedicated nine-person care team and undergoes pharmacogenomic testing. This genetic analysis aims to identify how an individual's body is likely to respond to specific medications, allowing for a more tailored and potentially more effective treatment plan. The regimen is further supplemented by what the company calls "nutrient repletion"—protocols designed to restore vitamins and amino acids depleted by substance use—and continuous remote monitoring to support patients in their daily lives.

NorthStar reports remarkable outcomes, claiming an 85.7% patient success rate and a Net Promoter Score (NPS) of 88.2, a measure of customer satisfaction that would be the envy of companies in any industry. While these figures are self-reported and have not been independently audited, they point to a level of patient engagement that the addiction treatment field has long struggled to achieve.

The scientific underpinnings of NorthStar's model reflect both established and emerging trends. The use of virtual care for substance use disorders has been validated by numerous studies, with research showing it can significantly improve treatment retention and accessibility. Telehealth saw a massive surge during the COVID-19 pandemic, and data suggests virtual programs can be as effective as, and sometimes more effective than, in-person care. Likewise, the field of pharmacogenomics is a key research priority for the National Institute on Drug Abuse (NIDA), which sees it as a vital tool for developing the next generation of personalized addiction treatments.

Navigating the Booming Digital Health Market

NorthStar's rise comes amid a historic boom in the virtual health market. The pandemic accelerated the adoption of telehealth by years, and investors have poured hundreds of millions of dollars into startups focused on addiction care. The market is now a bustling, competitive space filled with companies promising to deliver better, more accessible treatment through technology.

Key players include companies like Workit Health, which provides online therapy and medication-assisted treatment, and Pelago, which markets its substance use management platform directly to employers. The field also includes Boulder Care, a national telehealth solution for opioid use disorder that Dr. Wilson herself co-founded, underscoring her long-standing role as a pioneer in the space.

This rapid expansion, however, is not without challenges. The digital divide remains a significant barrier, as effective virtual care requires reliable internet access and a degree of digital literacy that not all patients possess. Furthermore, while virtual care offers convenience and removes the stigma that can be associated with visiting a clinic, some experts argue that it cannot fully replicate the nuanced, in-person interaction that can be crucial for those with severe or complex conditions. Balancing the scalability of technology with the profound human need for connection remains a central challenge for the entire industry.

From Clinical Pioneer to Policy Influencer

Dr. Wilson's appointment to the council is not merely a recognition of one company's success but the culmination of a career spent on the front lines of addiction medicine. A board-certified physician with over two decades of experience, her professional journey maps the evolution of modern addiction treatment. In 2009, she founded CleanSlate Addiction Treatment Centers, a network that helped pioneer office-based programs for opioid addiction when such an approach was still novel.

Her transition from founding clinical practices to leading technology-driven companies like Boulder Care and NorthStar reflects a deep-seated belief in leveraging innovation to solve systemic problems. This vision has attracted powerful allies, including former U.S. Representative Patrick Kennedy, a long-time champion of mental health parity, and life and business strategist Tony Robbins, who are both partners and supporters of NorthStar.

Her new role on the Health Care Council formalizes her transition from a clinical and business leader into a national policy influencer. With a seat at the table alongside the nation's most powerful healthcare executives and policymakers, Dr. Wilson is now uniquely positioned to advocate for the integration of technology, genetics, and long-term virtual support into the standard of care for addiction. Her presence ensures that the lessons learned from the fast-moving world of digital health startups will be part of the conversation shaping the future of American medicine.